曲拉西利预防肺癌化疗引起的骨髓抑制1例及文献分析  

Trilaciclib for prevention of chemotherapy⁃induced myelosuppression in lung cancer:a case report and literature review

作　　者：黄豪杰 陈韬 谢晓原[1] 池秀盈 孙佳婷 陈理明[1] HUANG Hao-jie;CHEN Tao;XIE Xiao-yuan;CHI Xiu-ying;SUN Jia-ting;CHEN Li-ming(The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,China;Medical College of Shantou University,Shantou 515041,China;Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]汕头大学医学院第一附属医院,汕头515041 [2]汕头大学医学院,汕头515041 [3]中山大学中山医学院,广州510080

出　　处：《中国新药杂志》2024年第1期68-72,共5页Chinese Journal of New Drugs

摘　　要：肺癌是我国恶性肿瘤中发病率和死亡率最高的癌症,非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌最主要的病理类型,约占肺癌总数的80%~85%。含铂双药化疗是驱动基因阴性晚期NSCLC标准的一线化疗方案。骨髓抑制(chemotherapy-induced myelosuppression,CIM)是肿瘤化疗最常见的毒性反应,包括中性粒细胞减少症、血小板减少症和贫血。目前,CIM的传统治疗手段都有一定的局限性,主要包括仅针对单一谱系、存在其他不良事件发生风险、治疗时间长、起效慢、易导致骨髓耗竭等。曲拉西利(trilaciclib)作为新型细胞周期蛋白依赖性激酶4/6(cyclin-dependent kinase 4/6,CDK4/6)抑制剂,通过诱导造血干/祖细胞(hematopoietic stem and progenitor cells,HSPCs)短暂停滞在G1期,保护其免受化疗损伤,在全系骨髓上起显著预防保护作用,显著降低三系骨髓抑制的发生率,具有高效性、选择性与可逆性,且安全性良好。本文报道1例曲拉西利预防肺癌化疗引发的骨髓抑制病例,以供同行参考。Lung cancer has the highest morbidity and mortality among malignant tumors in China,and non⁃small cell lung cancer(NSCLC)is the main pathological type of lung cancer,accounting for approximately 80%to 85%.Currently,platinum⁃based chemotherapy is still the standard first⁃line chemotherapy regimen for advanced driver⁃gene negative NSCLC,and the main adverse event is chemotherapy⁃induced myelosuppression(CIM),including neutropenia,thrombocytopenia,and anemia.At present,the traditional treatment of CIM have certain limitations,mainly including targeting only mono⁃lineage,having the risk of inducing other adverse events,long duration of treatment with a slow onset of action,and possibility of bone marrow depletion.As a novel cyclin⁃dependent kinase 4/6(CDK4/6)inhibitor,trilaciclib plays a significant role in multi⁃lineage bone marrow protection by inducing transient arrest in G1 phase with high efficiency,selectivity and reversibility.This article reports a patient with NSCLC who receiced trilaciclib for preventing CIM,aiming to provide reference basis for clinical practice.

关 键 词：非小细胞肺癌 化疗 骨髓抑制 曲拉西利 

分 类 号：R979.1[医药卫生—药品]